NEW YORK, Sept 26 (Reuters) - CollaGenex Pharmaceuticals Inc CGPI.O said on Wednesday it is abandoning development of its drug incyclinide for treating rosacea after a Phase 2 study found it was ineffective at reducing lesions.
In the trial of 197 rosacea patients, the drug did not demonstrate a greater reduction in inflammatory lesions than the patients on a placebo, the company said.
CollaGenex said it plans to conduct additional development work for the use incyclinide to treat acne. (Reporting by Chris Reiter)
